Noble Financial Thinks Electrocore’s Stock is Going to Recover

By Carrie Williams

In a report released today, Ahu Demir from Noble Financial reiterated a Buy rating on Electrocore (ECORResearch Report), with a price target of $4.00. The company’s shares closed last Monday at $0.92, close to its 52-week low of $0.32.

According to, Demir is a 1-star analyst with an average return of -10.4% and a 41.0% success rate. Demir covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, Dyadic International, and TherapeuticsMD.

Currently, the analyst consensus on Electrocore is a Moderate Buy with an average price target of $2.75, which is a 209.0% upside from current levels. In a report issued on May 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $1.50 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.64 and a one-year low of $0.32. Currently, Electrocore has an average volume of 1.72M.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.